Skip to main content
Caplight Logo









RxMen

RxMen

Private
New DelhiHealthcare & Life Scienceshttps://rxmen.com

Last Round

Seed

Sep 4, 2025

Total Funding Raised

$820,000

Momentum

Top 5%

of companies Caplight tracks

Company Overview

RxMen operates in Healthcare & Life Sciences and is based in New Delhi. Its latest recorded funding round was a Seed round in September 2025.

RxMen is a health-tech company that provides an online platform offering expert-guided, holistic solutions for men's sexual health and wellness.

Sector

Healthcare & Life Sciences

Verticals

Telemedicine, D2C Brands, Subscription Commerce

Business Model

B2C

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

RxMen Comparables

Compare RxMen with similar companies based on industry and business-model similarity.

RxMen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MenRx
91%
Bold Care
88%
Allo Health
87%
Book a demo to see all comparables

For institutional investors. Book with your work email.

RxMen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 4, 2025
Pre SeedMar 15, 2024
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

RxMen Investors

Notable investors and investment history

RxMen investors
InvestorRounds
ProsusSeed
Inflection Point VenturesSeed
PointOne CapitalPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 15, 2026

    Grew 26% QoQ, from 65 to 82 employees.

  • Jul 26, 2026

    Monthly visitors grew 135% MoM, reaching 42.1K.

Book a demo to see all signals

For institutional investors. Book with your work email.

RxMen Filings

Explore SEC and related filing metadata, where available.

RxMen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about RxMen's valuation, stock price, and market status.

Is RxMen a public or private company?

RxMen is a private company.

What is the current stock price of RxMen?

RxMen is a private company, so its shares have no public market price. Caplight tracks RxMen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is RxMen worth (valuation)?

Valuation information for RxMen is not publicly available.

Can I buy RxMen stock?

RxMen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was RxMen's last funding round?

RxMen's most recent funding round was Seed on September 4, 2025.

Who are the main investors in RxMen?

Key investors in RxMen include Inflection Point Ventures, PointOne Capital.

Will RxMen IPO soon?

No public IPO plans have been announced for RxMen.

How can I track RxMen secondary market activity?

Caplight tracks bids, offers, and trades in RxMen's shares on secondary markets.

Firmographic Details

HeadquartersNew Delhi
Employee Range66
Year Founded2023
Last FundingSep 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?